Besthof Robert 4

4 · NRX Pharmaceuticals, Inc. · Filed Nov 2, 2021

Form 4

Period: 2021-08-16

Chief Comm. & Patient Officer

Transactions

Exercise/Conversion
Common Stock
2021-08-16$0.20/sh+63,710$12,742→ 63,710 total
Sale
Common Stock
2021-09-15$11.76/sh−40,000$470,400→ 23,710 total
Award
Restricted Stock Units
2021-08-16+36,290→ 36,290 total
→ Common Stock (36,290 underlying)
Conversion
Employee Stock Option (Right to buy)
2021-08-16$0.20/sh−100,000$20,000→ 247,200 total
Exercise: $0.20Exp: 2026-03-01→ Common Stock (100,000 underlying)

Footnotes (2)

[F1]The options are fully vested.
[F2]Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.

Documents

1 file